PD 131628

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525839

CAS#: 127967-03-7

Description: PD 131628 is a new fluoroquinolone, the bioactive form of PD 131112 or CI-990, used against anaerobic bacteria. Research shows promise for therapy of infections with penicillin-resistant and -susceptible pneumococci.

Chemical Structure

img
PD 131628
CAS# 127967-03-7
Instruction

Theoretical Analysis

MedKoo Cat#: 525839
Name: PD 131628
CAS#: 127967-03-7
Chemical Formula: C16H17FN4O3
Exact Mass: 332.13
Molecular Weight: 332.330
Elemental Analysis: C, 57.83; H, 5.16; F, 5.72; N, 16.86; O, 14.44

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: PD-131628; PD131628; PD 131628

IUPAC/Chemical Name: (S)-7-(3-aminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

InChi Key: MUKSDTOOLRNSIO-QMMMGPOBSA-N

InChi Code: InChI=1S/C16H17FN4O3/c17-12-5-10-13(22)11(16(23)24)7-21(9-1-2-9)14(10)19-15(12)20-4-3-8(18)6-20/h5,7-9H,1-4,6,18H2,(H,23,24)/t8-/m0/s1

SMILES Code: O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@@H](N)CC4)=N3)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 332.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sewell DL, Barry AL, Allen SD, Fuchs PC, Murray PR, Tenover FC. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)). J Antimicrob Chemother. 1996 Jan;37(1):139-43. PubMed PMID: 8647755.
2: Wexler HM, Molitoris E, Reeves D, Finegold SM. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria. J Antimicrob Chemother. 1994 Oct;34(4):579-84. PubMed PMID: 7868409.
3: Barry AL, Fuchs PC, Citron DM, Allen SD, Wexler HM. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin. J Antimicrob Chemother. 1993 Jun;31(6):893-900. PubMed PMID: 8395494.
4: Qadri SM, Ueno Y. Susceptibility of Brucella melitensis to the new fluoroquinolone PD 131628: comparison with other drugs. Chemotherapy. 1993 Mar-Apr;39(2):128-31. PubMed PMID: 8384544.
5: Lewin C, Doherty C, Govan J. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob Agents Chemother. 1993 Jan;37(1):123-5. PubMed PMID: 8431009; PubMed Central PMCID: PMC187617.
6: Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):856-9. PubMed PMID: 1323956; PubMed Central PMCID: PMC189460.
7: Nord CE, Hagelbäck A. Susceptibility of anaerobic bacteria to PD 131628. Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):68-71. PubMed PMID: 1314176.
8: Barry AL, Fuchs PC. Antistaphylococcal activity of the fluoroquinolones CI-960, PD 131628, sparfloxacin, ofloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991 Mar;10(3):168-71. PubMed PMID: 2060518.
9: Cohen MA, Huband MD. In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs. J Antimicrob Chemother. 1997 Aug;40(2):308-9. PubMed PMID: 9302005.
10: Van Rensburg CE, Jooné GK, Anderson R. An in vitro investigation of the bioactivities of ciprofloxacin and the new fluoroquinolone agents clinafloxacin (CI-960) and PD 131628 against Mycobacterium tuberculosis in human macrophages. Chemotherapy. 1995 Jul-Aug;41(4):234-8. PubMed PMID: 7555202.
11: Sewell DL, Barry AL, Allen SD, Fuchs PC, Jorgensen JH, Tenover F. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628). Diagn Microbiol Infect Dis. 1995 Mar;21(3):175-9. PubMed PMID: 7648838.
12: Fuchs PC, Barry AL, Pfaller MA. Antibacterial activity of PD 131628 and proposed disc diffusion susceptibility test criteria. J Antimicrob Chemother. 1994 Jun;33(6):1147-54. PubMed PMID: 7928808.
13: Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin. Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. PubMed PMID: 8192468; PubMed Central PMCID: PMC284459.
14: Anderson R, Jooné GK. In vitro investigation of the intraphagocytic bioactivities of ciprofloxacin and the new fluoroquinolone agents, clinafloxacin (CI-960) and PD 131628. Chemotherapy. 1993 Nov-Dec;39(6):424-31. PubMed PMID: 8222871.
15: Ford AS, Baltch AL, Smith RP, Ritz W. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents. J Antimicrob Chemother. 1993 Apr;31(4):523-32. PubMed PMID: 8390434.
16: Cooper MA, Andrews JM, Wise R. In-vitro activity of PD 131628, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1992 May;29(5):519-27. PubMed PMID: 1320603.
17: Lewin CS. Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628. J Med Microbiol. 1992 May;36(5):353-7. PubMed PMID: 1316970.
18: Cohen MA, Huband MD, Mailloux GB, Yoder SL, Roland GE, Domagala JM, Heifetz CL. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991 Jan;35(1):141-6. PubMed PMID: 2014970; PubMed Central PMCID: PMC244955.